 This is a pilot, single center, prospective, double blinded, randomized study comparing epoetin alfa versus placebo. Eligible patients will just have undergone a major abdominal operation for malignancy esophagectomy, gastrectomy, partial hepatectomy, partial pancreatectomy, or low anterior resection of rectum and have a post-operative hemoglobin greater than 8 gdL and less than 11 gdL on post-operative day 1. On post-operative day 1 patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa or placebo. On post-operative day 8, the patients will receive an additional dose of epoetin alfa or placebo depending on randomization assignment and Hgb level. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool FACT-An to assess their fatigue related to anemia. 